1225383-33-4 Usage
Description
(S)-2-(2S,3R)-3-[(9H-fluoren-9-yl)methoxy]carbonylamino-2-hydroxy-4-phenylbutanamido-4-methylpentanoic acid is a complex organic compound with a molecular structure that features a 2-hydroxy-4-phenylbutanamido and 4-methylpentanoic acid group. It also contains a fluorenyl methoxy carbonylamino group, which contributes to its potential significance in the pharmaceutical industry. (S)-2-(2S,3R)-3-[(9H-fluoren-9-yl)methoxy]carbonylamino-2-hydroxy-4-phenylbutanamido-4-methylpentanoic acid is optically active, meaning it can rotate polarized light, and its structure suggests that it may possess pharmacological properties and play a role in biochemical processes within the human body. Further research and testing are necessary to fully comprehend its potential applications and effects.
Uses
Used in Pharmaceutical Industry:
(S)-2-(2S,3R)-3-[(9H-fluoren-9-yl)methoxy]carbonylamino-2-hydroxy-4-phenylbutanamido-4-methylpentanoic acid is used as a potential pharmaceutical compound for its unique molecular structure and optical activity. Its application in this industry is due to the possibility of it possessing pharmacological properties and being involved in biochemical processes within the human body.
Used in Research and Development:
In the field of research and development, (S)-2-(2S,3R)-3-[(9H-fluoren-9-yl)methoxy]carbonylamino-2-hydroxy-4-phenylbutanamido-4-methylpentanoic acid serves as a subject for further investigation. Its use in this context is to explore its potential applications, pharmacological properties, and effects on biochemical processes, which may lead to the development of new drugs or therapies.
Used in Drug Delivery Systems:
(S)-2-(2S,3R)-3-[(9H-fluoren-9-yl)methoxy]carbonylamino-2-hydroxy-4-phenylbutanamido-4-methylpentanoic acid may be utilized in the development of novel drug delivery systems. Its application in this area is to improve the delivery, bioavailability, and therapeutic outcomes of other pharmaceutical compounds by potentially acting as a carrier or enhancer.
Check Digit Verification of cas no
The CAS Registry Mumber 1225383-33-4 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,2,2,5,3,8 and 3 respectively; the second part has 2 digits, 3 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 1225383-33:
(9*1)+(8*2)+(7*2)+(6*5)+(5*3)+(4*8)+(3*3)+(2*3)+(1*3)=134
134 % 10 = 4
So 1225383-33-4 is a valid CAS Registry Number.
1225383-33-4Relevant articles and documents
Protein knockdown using methyl bestatin-ligand hybrid molecules: Design and synthesis of inducers of ubiquitination-mediated degradation of cellular retinoic acid-binding proteins
Itoh, Yukihiro,Ishikawa, Minoru,Hashimoto, Yuichi,Naito, Mikihiko
supporting information; experimental part, p. 5820 - 5826 (2010/07/05)
Induction of selective degradation of target proteins by small molecules (protein knockdown) would be useful for biological research and treatment of various diseases. To achieve protein knockdown, we utilized the ubiquitin ligase activity of cellular inhibitor of apoptosis protein 1 (cIAP1), which is activated by methyl bestatin (MeBS, 2). We speculated that formation of an artificial (nonphysiological) complex of cIAP1 and a target protein would be induced by a hybrid molecule consisting of MeBS (2) linked to a ligand of the target protein, and this would lead to cIAP1-mediated ubiquitination and subsequent proteasomal degradation of the target protein. To verify this hypothesis, we focused on cellular retinoic acid-binding proteins (CRABP-I and -II) and designed hybrid molecules (compounds 4) consisting of MeBS (2) coupled via spacers of various lengths to all-trans retinoic acid (ATRA, 3), a ligand of CRABPs. Compounds 4 induced selective loss of CRABP-I and -II proteins in cells. We confirmed that 4b induced formation of a complex of cIAP1 and CRABP-II in vitro and induced proteasomal degradation of CRABP-II in cells. When neuroblastoma IMR-32 cells were treated with 4b, the level of CRABP-II was reduced and cell migration was inhibited, suggesting potential value of CRABP-II-targeting therapy for controlling tumor metastasis. Our results indicate that 4b possesses sufficient activity, permeability, and stability in cells to be employed in cellular assays. Hybrid molecules such as 4 should be useful not only as chemical tools for studying the biological/physiological functions of CRABPs but also as candidate therapeutic agents targeting CRABPs.
